This is a working overview of 白蛋白结合, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-20. Anything still debated is marked as such rather than presented as settled.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Water and aqueous buffers | Near neutral pH |
| Storage temperature | Minus 20 to minus 80 C | Long-term, lyophilized |
| Analytical method | RP-HPLC | Purity assessment |
| Typical purity | Greater than 95 percent | Research-grade material |
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
=== DNA uptake mechanism === When DNA uptake and subsequent expression was first demonstrated in vivo in muscle cells, these cells were thought to be unique because of their extensive network of T-tubules. Using electron microscopy, it was proposed that DNA uptake was facilitated by caveolae (or, non-clathrin coated pits). However, subsequent research revealed that other cells (such as keratinocytes, fibroblasts and epithelial Langerhans cells) could also internalize DNA. The mechanism of DNA uptake is not known. Two theories dominate – that in vivo uptake of DNA occurs non-specifically, in a method similar to phago- or pinocytosis, or through specific receptors. These might include a 30kDa surface receptor, or macrophage scavenger receptors. The 30kDa surface receptor binds specifically to 4500-bp DNA fragments (which are then internalised) and is found on professional APCs and T-cells. Macrophage scavenger receptors bind to a variety of macromolecules, including polyribonucleotides and are thus candidates for DNA uptake. Receptor-mediated DNA uptake could be facilitated by the presence of polyguanylate sequences. Gene gun delivery systems, cationic liposome packaging, and other delivery methods bypass this entry method, but understanding it may be useful in reducing costs (e.g. by reducing the requirement for cytofectins), which could be important in animal husbandry.
=== Microscopy === Other microscopy techniques are commonly used in tandem with NanoSIMS that allow for multiple types of information to be obtained, such as taxonomic information through fluorescence in situ hybridization (FISH) or identification of additional physiological or microstructural features via transmission electron microscopy (TEM) or scanning electron microscopy (SEM).
=== Types === Plasma retinol-binding protein, the retinol transport vehicle in serum. CRBP I/II, cellular-binding proteins involved in transport of retinol and metabolites into retinyl esters for storage or into retinoic acid. CRABPs, cellular retinoic acid–binding proteins capable of binding retinol and retinoic acid with high affinity. It has also been characterized that CRABPs are involved in many aspects of the retinoic acid signaling pathway such as the regulation and availability of retinoic acid to nuclear receptors.
Alessio Ciulli (born 22 July 1977) is an Italian British biochemist. Currently, he is the Professor of Chemical & Structural Biology at the School of Life Sciences, University of Dundee, where he founded and directs Dundee' new Centre for Targeted Protein Degradation (CeTPD). He is also the scientific co-founder and advisor of Amphista Therapeutics.
Classification and Evolution Regulation, Development, and Molecular Diversity Aquatic Environments and Populations Ecology and Biodiversity Management History of Earth Men, Nature, and Societies, and Prehistory The diffusion departments are:
Sources: en.wikipedia.org
Nuclear fuel data and analysis from the U.S. Energy Information Administration World Uranium deposit maps Dittmar, William (1888). "Uranium" . Encyclopædia Britannica. Vol. XXIV (9th ed.). p. 7. Annotated bibliography for uranium from the Alsos Digital Library NLM Hazardous Substances Databank – Uranium, Radioactive CDC – NIOSH Pocket Guide to Chemical Hazards ATSDR Case Studies in Environmental Medicine: Uranium Toxicity Archived 4 February 2016 at the Wayback Machine U.S. Department of Health and Human Services Uranium at The Periodic Table of Videos (University of Nottingham)
== January 2, 1982 (Saturday) == The Army of Guatemala, in a campaign by President Fernando Lucas Garcia, killed 35 civilians in the village of Pichec, in the Baja Verapaz Department near Rabinal, for their support of the Guerrilla Army of the Poor (Ejército Guerrillero de los Pobres). The killing was the third of the mostly Maya residents of Pichec, in less than nine weeks, with 32 men killed on November 1 and 30 more on November 22. Ahmad Fuad Mohieddin was selected to become the new Prime Minister of Egypt at the request of President Hosni Mubarak, who had held the position of both president and premier since the October 6 assassination of Anwar Sadat. In Denmark, the popular television series Matador broadcast its final episode, watched by 3.5 million viewers in a nation of 5.1 million people. The Clemson University Tigers football team finished in first place in both polls recognized by the NCAA for determining the U.S. major university football championship. In the AP poll of 49 sportswriters, Clemson received 977 points (based on 20 points for a first place vote, 19 for second place, etc.) and the Texas Longhorns 862 points. In the UPI poll of 37 coaches, Clemson had 547 points and the Pitt Panthers 472. In an NFL playoff game nicknamed the "Epic in Miami" as well as "The Game No One Should Have Lost", and ranked in a 2020 survey as the fourth greatest NFL game in the 20th century, the San Diego Chargers defeated the Miami Dolphins, 41 to 38, in overtime, after blowing a 24 to 0 lead in the first quarter.
=== Pharmacological treatment === Since the early 2020s, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become an increasingly important component of obesity treatment in Brazil. The Brazilian Health Regulatory Agency approved liraglutide for weight management in adolescents in August 2020, followed by the approval of semaglutide for expanded use in September 2023. These approvals introduced the first GLP-1 receptor agonists specifically indicated for obesity treatment in Brazil. Subsequent years saw rapid growth in the use of semaglutide and other GLP-1-based therapies, concentrated predominantly in higher-income regions. The expansion was accompanied by increasing regulatory attention regarding off-label use and counterfeit products. Brazilian clinical guidelines recommend GLP-1 receptor agonists as part of evidence-based obesity management in selected patients. A 2025 position statement issued jointly by five Brazilian medical societies reinforced the role of GLP-1 receptor agonists — including liraglutide, semaglutide, and tirzepatide - in the pharmacological management of obesity and prevention of cardiovascular complications. Internationally, semaglutide has been recognised as a significant development in obesity pharmacotherapy, with clinical trials demonstrating weight reductions of approximately 15–17% of baseline body weight in adults without type 2 diabetes.
== Treatment == Management of the dawn phenomenon varies by patient and thus should be done with regular assistance from a patient's physician. Some treatment options include, but are not limited to, dietary modifications, increased exercise before breakfast and during the evening, and oral anti-hyperglycemic medications if a patient's HbA1c is > 7%. Insulin pumps can also be used to provide continuous subcutaneous infusions and are regarded as the gold standard for managing the dawn phenomenon in type 1 diabetics. Continuous glucose monitoring systems (CGM) are used to monitor changes in blood sugar overnight.
May 31: Decree regarding the admission of women to the role of Foreign Trade Advisor. June 14: The issuance of a passport no longer requires a husband's authorization for a married woman. September 30: Decree establishing a Higher Council for Child Protection. 1938
Sources: en.wikipedia.org
== Strategies == Before designing a distribution system, the supplier needs to determine what distribution channel to achieve in broad terms. The approach to distributing products or services depends on a number of factors including the type of product, especially perishability; the market served; the geographic scope of operations and the firm's overall mission and vision. The process of setting out a broad statement of the aims and objectives of a distribution channel is a strategic level decision.
== Prognosis == Lyme disease's typical first sign, the erythema migrans (EM) rash, resolves within several weeks even without treatment. However, in untreated people, the infection often disseminates to the nervous system, heart or joints, possibly causing permanent damage to body tissues. People who receive recommended antibiotic treatment within several days of the appearance of an initial EM rash have the best prospects. Recovery may not be total or immediate. The percentage of people achieving full recovery in the United States increases from about 64–71% at the end of treatment for EM rash to about 84–90% after 30 months; higher percentages are reported in Europe. Treatment failure, i.e. persistence of original or appearance of new signs of the disease, occurs only in a few people. Remaining people are considered cured but continue to experience subjective symptoms, e.g., joint or muscle pains or fatigue. These symptoms are usually mild and nondisabling. People treated only after nervous system manifestations of the disease may end up with objective neurological deficits, in addition to subjective symptoms. In Europe, an average of 32–33 months after initial Lyme symptoms in people treated mostly with doxycycline 200 mg for 14–21 days, the percentage of people with lingering symptoms was much higher among those diagnosed with neuroborreliosis (50%) than among those with only an EM rash (16%).
=== 1971–1976: Eminence === In March 1971, IBT hired Paul L. Wright, one of Monsanto's toxicologists, to oversee its PCB testing. Donovan E. Gordon joined IBT as a pathologist in August 1971, and IBT finalized its safety analysis of PCBs in November 1971. Irregularities in IBT's data were discovered in April 1976 by Adrian Gross, an investigator at the Food and Drug Administration, whose aide retrieved one of the laboratory's naproxen studies that had been conducted for Syntex, a pharmaceutical company recently outed by a whistleblower. Gross examined the study further; it struck him as being unrealistic and piqued his interest. The FDA proceeded to probe IBT, and Gross personally inspected its facilities on April 11 and July 12, 1976. During Gross' physical inspection of the laboratory, he gained access to the study's raw safety data and found frequent references to an unknown acronym, "TBD/TDA," which he said perplexed him until learning that it denoted a testing animal whose body had "too badly decomposed."
In 1955, a USAF surgeon who advised the US Surgeon General wrote an article on how to make cars safer for those riding in it. Aside from the usual safety features, such as seat belts and padded dashboards, bumper shocks were introduced. In 1956, Ford tried unsuccessfully to interest Americans in purchasing safer cars with their Lifeguard safety package. (Its attempt nevertheless earns Ford Motor Trend's "Car of the Year" award for 1956.) In 1958, the United Nations established the World Forum for Harmonization of Vehicle Regulations, an international standards body advancing auto safety. Many of the most life saving safety innovations, like seat belts and roll cage construction were brought to market under its auspices. That same year, Volvo engineer Nils Bohlin invented and patented the three-point lap and shoulder seat belt, which became standard equipment on all Volvo cars in 1959. Over the next several decades, three-point safety belts were gradually mandated in all vehicles by regulators throughout the industrialised world. In 1959, American Motors Corporation offered the first optional head rests for the front seat. Also in 1959, the Cadillac Cyclone concept by Harley Earl had "a radar-based crash-avoidance system" located on the nose cones of the vehicle that would make audible and visual signals to the driver if there were obstacles in the vehicle's path.
Sources: en.wikipedia.org
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.
Repeated temperature cycling can promote aggregation and peptide degradation. Dividing material into single-use aliquots limits this risk.
Mass spectrometry is commonly used to confirm molecular mass and detect structural modifications. It is often paired with chromatographic purity assessment.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.